Results 181 to 190 of about 30,778 (256)

Pre-therapy dose prediction in targeted radionuclide therapy using semi-supervised learning: An in-silico preliminary study

Jing Zhang, Alexandre Bousse, Yanbin Li, Song Xue, Ke Shi, Dimitris Visvikis, Julien Bert   +6 more
openalex   +2 more sources

IL-33 as a Marker of Poor Early Response in Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy. [PDF]

Int J Mol Sci
Vuleta Nedic K, Gajovic N, Jovanovic I, Jurisevic M, Jovanovic M, Jakovljević S, Popovic B, Djordjevic J, Ignjatovic V, Vukomanovic V.   +9 more
europepmc   +1 more source

Validation of the collapsed-cone superposition for whole-body patient-specific dosimetry in [177Lu]Lu-PSMA-617 radionuclide therapy. [PDF]

Med Phys
Terro A, Perret S, Dumouchel A, Tonnelet D, Edet-Sanson A, Vera P, Decazes P, Dieudonné A.   +7 more
europepmc   +1 more source

Targeted radionuclide therapy and diagnostic imaging of SSTR positive neuroendocrine tumors: a clinical update in the new decade. [PDF]

Front Nucl Med
Haugh KN, Sanwick AM, Chaple IF.
europepmc   +1 more source

Targeted Radionuclide Therapy Activates Prodrugs for Treating Metastasis. [PDF]

ACS Cent Sci
Guo Z, Wang X, Han Y, Shen S, Tian P, Hu Y, Ding Z, Fu Q, Liu Z.   +8 more
europepmc   +1 more source

Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy

, 2018
Dongyoul Lee, Mengshi Li, Bryan P. Bednarz, Michael K. Schultz   +3 more
openalex   +2 more sources

Drug-Induced Liver Injury Secondary to Radionuclide Therapy With Lutetium-177 Vipivotide Tetraxetan in a Patient With Metastatic Castrate-Resistant Prostate Cancer. [PDF]

ACG Case Rep J
Lee BT, Kankotia RJ, Braxton D.
europepmc   +1 more source

Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors. [PDF]

J Neuroendocrinol
Santo G, di Santo G, Cicone F, Virgolini I.   +3 more
europepmc   +1 more source

Targeted radionuclide therapy for gliomas: Emerging clinical trial landscape. [PDF]

Neuro Oncol
Weller M, Albert NL, Galldiks N, Bink A, Preusser M, Sulman EP, Treyer V, Wen PY, Tonn JC, Le Rhun E.   +9 more
europepmc   +1 more source

Peptide Receptor Radionuclide Therapy with Lu-177-DOTATATE and Monitoring with Somatostatin Receptor PET/CT in Patients with Advanced Differentiated Thyroid Carcinoma. [PDF]

Mol Imaging Biol
Kunte SC, Wenter VU, Holzgreve A, Sheikh GT, Widjaja L, Gildehaus FJ, Lindner S, Schirrmacher R, Spitzweg C, Auernhammer CJ, Werner RA, Zacherl MJ.   +11 more
europepmc   +1 more source